Cargando…
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
BACKGROUND: The dopaminergic partial agonism of the so-called third-generation antipsychotics (TGAs; aripiprazole, brexpiprazole, cariprazine) is hypothesized to cause impulse control disorders (ICDs). Relevant warnings by the Food and Drug Administration (FDA) were posted on aripiprazole (2016) and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515127/ https://www.ncbi.nlm.nih.gov/pubmed/35639870 http://dx.doi.org/10.1093/ijnp/pyac031 |
_version_ | 1784798423034101760 |
---|---|
author | Fusaroli, Michele Raschi, Emanuel Giunchi, Valentina Menchetti, Marco Rimondini Giorgini, Roberto De Ponti, Fabrizio Poluzzi, Elisabetta |
author_facet | Fusaroli, Michele Raschi, Emanuel Giunchi, Valentina Menchetti, Marco Rimondini Giorgini, Roberto De Ponti, Fabrizio Poluzzi, Elisabetta |
author_sort | Fusaroli, Michele |
collection | PubMed |
description | BACKGROUND: The dopaminergic partial agonism of the so-called third-generation antipsychotics (TGAs; aripiprazole, brexpiprazole, cariprazine) is hypothesized to cause impulse control disorders (ICDs). Relevant warnings by the Food and Drug Administration (FDA) were posted on aripiprazole (2016) and brexpiprazole (2018). Our study investigated the FDA Adverse Event Reporting System and the pharmacodynamic CHEMBL database to further characterize TGA-induced ICDs. METHODS: We downloaded and pre-processed the FDA Adverse Event Reporting System up to December 2020. We adapted Bradford Hill criteria to assess each TGA’s —and secondarily other antipsychotics’—causal role in inducing ICDs (pathological gambling, compulsive shopping, hyperphagia, hypersexuality), accounting for literature and disproportionality. ICD clinical features were analyzed, and their pathogenesis was investigated using receptor affinities. RESULTS: A total of 2708 reports of TGA-related ICDs were found, primarily recording aripiprazole (2545 reports, 94%) among the drugs, and gambling (2018 reports, 75%) among the events. Bradford-Hill criteria displayed evidence for a causal role of each TGA consistent across subpopulations and when correcting for biases. Significant disproportionalities also emerged for lurasidone with compulsive shopping, hyperphagia, and hypersexuality, and olanzapine and ziprasidone with hyperphagia. Time to onset varied between days and years, and positive dechallenge was observed in 20% of cases. Frequently, co-reported events were economic (50%), obsessive-compulsive (44%), and emotional conditions (34%). 5-Hydroxytryptamine receptor type 1a agonism emerged as an additional plausible pathogenetic mechanism. CONCLUSIONS: We detected an association between TGAs and ICDs and identified a new signal for lurasidone. ICD characteristics are behavior specific and may heavily impact on life. The role of 5-Hydroxytryptamine receptor type 1a agonism should be further explored. |
format | Online Article Text |
id | pubmed-9515127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95151272022-09-28 Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System Fusaroli, Michele Raschi, Emanuel Giunchi, Valentina Menchetti, Marco Rimondini Giorgini, Roberto De Ponti, Fabrizio Poluzzi, Elisabetta Int J Neuropsychopharmacol Regular Research Articles BACKGROUND: The dopaminergic partial agonism of the so-called third-generation antipsychotics (TGAs; aripiprazole, brexpiprazole, cariprazine) is hypothesized to cause impulse control disorders (ICDs). Relevant warnings by the Food and Drug Administration (FDA) were posted on aripiprazole (2016) and brexpiprazole (2018). Our study investigated the FDA Adverse Event Reporting System and the pharmacodynamic CHEMBL database to further characterize TGA-induced ICDs. METHODS: We downloaded and pre-processed the FDA Adverse Event Reporting System up to December 2020. We adapted Bradford Hill criteria to assess each TGA’s —and secondarily other antipsychotics’—causal role in inducing ICDs (pathological gambling, compulsive shopping, hyperphagia, hypersexuality), accounting for literature and disproportionality. ICD clinical features were analyzed, and their pathogenesis was investigated using receptor affinities. RESULTS: A total of 2708 reports of TGA-related ICDs were found, primarily recording aripiprazole (2545 reports, 94%) among the drugs, and gambling (2018 reports, 75%) among the events. Bradford-Hill criteria displayed evidence for a causal role of each TGA consistent across subpopulations and when correcting for biases. Significant disproportionalities also emerged for lurasidone with compulsive shopping, hyperphagia, and hypersexuality, and olanzapine and ziprasidone with hyperphagia. Time to onset varied between days and years, and positive dechallenge was observed in 20% of cases. Frequently, co-reported events were economic (50%), obsessive-compulsive (44%), and emotional conditions (34%). 5-Hydroxytryptamine receptor type 1a agonism emerged as an additional plausible pathogenetic mechanism. CONCLUSIONS: We detected an association between TGAs and ICDs and identified a new signal for lurasidone. ICD characteristics are behavior specific and may heavily impact on life. The role of 5-Hydroxytryptamine receptor type 1a agonism should be further explored. Oxford University Press 2022-05-27 /pmc/articles/PMC9515127/ /pubmed/35639870 http://dx.doi.org/10.1093/ijnp/pyac031 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of CINP. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Regular Research Articles Fusaroli, Michele Raschi, Emanuel Giunchi, Valentina Menchetti, Marco Rimondini Giorgini, Roberto De Ponti, Fabrizio Poluzzi, Elisabetta Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System |
title | Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System |
title_full | Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System |
title_fullStr | Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System |
title_full_unstemmed | Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System |
title_short | Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System |
title_sort | impulse control disorders by dopamine partial agonists: a pharmacovigilance-pharmacodynamic assessment through the fda adverse event reporting system |
topic | Regular Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515127/ https://www.ncbi.nlm.nih.gov/pubmed/35639870 http://dx.doi.org/10.1093/ijnp/pyac031 |
work_keys_str_mv | AT fusarolimichele impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem AT raschiemanuel impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem AT giunchivalentina impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem AT menchettimarco impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem AT rimondinigiorginiroberto impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem AT depontifabrizio impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem AT poluzzielisabetta impulsecontroldisordersbydopaminepartialagonistsapharmacovigilancepharmacodynamicassessmentthroughthefdaadverseeventreportingsystem |